lines recommend consideration of statin therapy based on age, low-density lipoprotein cholesterol (LDL-C) level and other cardiovascular risk factors. We evaluated dyslipidaemia prevalence, statin therapy use, and associations between not meeting target LDL-C [<100 mg/dL (<5.55 mmol/L)] and other cardiovascular disease (CVD) risk factors in individuals aged 10 to <40 years in the T1D Exchange clinic registry. In 7223 participants, statin use was 2% in 10 to <18 year olds, 4% in 18 to <25 year olds, and 21% in 25 to <40 year olds. Individuals not on statin therapy with LDL-C above target were more likely to have ≥1 additional CVD risk factor(s) than those with LDL-C in the target range for all age groups (all P < 0.01). While most individuals not on statin therapy had LDL-C in the target range, those who did not were more likely to have ≥1 additional CVD risk factor(s), and therefore longitudinal study of lipid levels and statin use is needed to see if treatment of dyslipidaemia to target LDL-C levels may lower the risk of future CVD in individuals aged 10 to <40 years with type 1 diabetes. 
For individuals aged 10 to <40 years with type 1 diabetes and dyslipidaemia, US national guidelines recommend consideration of statin therapy based on age, low-density lipoprotein cholesterol (LDL-C) level and other cardiovascular risk factors. We evaluated dyslipidaemia prevalence, statin therapy use, and associations between not meeting target LDL-C [<100 mg/dL (<5.55 mmol/L)] and other cardiovascular disease (CVD) risk factors in individuals aged 10 to <40 years in the T1D Exchange clinic registry. In 7223 participants, statin use was 2% in 10 to <18 year olds, 4% in 18 to <25 year olds, and 21% in 25 to <40 year olds. Individuals not on statin therapy with LDL-C above target were more likely to have ≥1 additional CVD risk factor(s) than those with LDL-C in the target range for all age groups (all P < 0.01). While most individuals not on statin therapy had LDL-C in the target range, those who did not were more likely to have ≥1 additional CVD risk factor(s), and therefore longitudinal study of lipid levels and statin use is needed to see if treatment of dyslipidaemia to target LDL-C levels may lower the risk of future CVD in individuals aged 10 to <40 years with type 1 diabetes. 
| RESULTS
The analysis cohort included 7223 participants (53% ages 10-<18, 28% ages 18-<25, and 19% ages 25-<40 years) with mean age 20 AE 7 years, diabetes duration 11 AE 6 years, 79% non-Hispanic White, and 50% female. Mean total cholesterol, LDL-C, high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) were similar across age groups (Table 1) .
Statin use in the 10 to <18 years group was 2%, 4% in the 18 to <25 years group, and 21% in the 25 to <40 years group. Statin users in the 10 to <18 years group were older with longer T1D duration, lower annual household income, and higher BMI (Table 2; all P < 0.01). Statin users in the 18 to <25 years group were more likely to have longer diabetes duration and lower annual household income (both P < 0.01). Statin users in the 25 to <40 years group were more likely to be older and male, and to have longer type 1 diabetes duration, higher BMI, and hypertension (all P < 0.01).
Mean LDL-C was higher among statin users than non-users across all age groups [10-<18 
